Hologic Inc.
Hologic, Inc. Authorizes New $1.5 Billion Stock Repurchase Program
Summary
On September 12, 2024, Hologic, Inc.'s Board of Directors authorized a new stock repurchase program to repurchase up to $1.5 billion of the Company's outstanding common stock over a five-year term. This authorization is in addition to the existing program, which has approximately $190 million remaining as of the same date. The timing and method of repurchases will be determined by the Company's management based on market and financial conditions.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement